Skip to main content
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Table 6 Relationship between hormones and QOLIE-31 domains

From: Determinants of quality of life in Nigerian female patients with epilepsy on carbamazepine and levetiracetam monotherapy

Variables

Total QOLIE-TS

Seizure Worry

Overall quality of life

Emotional Well-being

Energy

Cognitive functioning

Medication Effects

Social Functioning

FP: FSH

        

 Df

62,37

62, 37

62, 37

62, 37

62, 37

62, 37

62, 37

62, 37

 F

1.444

1.570

1.313

1.233

2.323

1.576

1.130

1.596

 p

0.116

0.071

0.188

0.249

0.003*

0.069

0.349

0.064

FP: LH

        

 Df

61,38

61, 38

61, 38

61, 38

61, 38

61, 38

61, 38

61, 38

 F

1.354

2.168

1.232

1.235

2.346

1.459

1.159

1.542

 p

0.160

0.006*

0.248

0.245

0.003*

0.107

0.317

0.078

FP: PR

        

 Df

56,43

56, 43

56, 43

56, 43

56, 43

56, 43

56, 43

56, 43

 F

1.674

1.610

1.226

1.202

1.718

1.548

1.114

1.957

 p

0.040*

0.053

0.245

0.267

0.033*

0.069

0.358

0.012*

FP:EST

        

 Df

70,29

70, 29

70, 29

70, 29

70, 29

70, 29

70, 29

70, 29

 F

2.185

3.702

1.260

1.718

2.665

2.345

1.102

2.707

 p

0.011*

0.000*

0.248

0.054

0.002*

0.006*

0.396

0.002*

FP:PRL

        

 Df

52,46

52, 46

52, 46

52, 46

52, 46

52, 46

52, 46

52, 46

 F

2.331

2.761

1.797

2.142

2.358

2.082

1.385

2.156

 p

0.002*

0.000*

0.022*

0.005*

0.002*

0.006*

0.132

0.004*

FP: LH:FSH

        

 Df

62,35

62, 35

62, 35

62, 35

62, 35

62, 35

62, 35

62, 35

 F

1.350

2.063

1.186

1.167

1.783

1.573

1.015

1.451

 p

0.170

0.011*

0.296

0.315

0.033*

0.074

0.492

0.118

LP: FSH

        

 Df

62,37

62, 37

62, 37

62, 37

62, 37

62, 37

62, 37

62, 37

 F

1.959

1.786

1.550

2.012

3.482

1.610

1.633

1.827

 p

0.015*

0.030*

0.077

0.012*

 

0.061

0.055

 

LP: LH

        

 Df

66,33

66, 33

66, 33

66, 33

66, 33

66, 33

66, 33

66, 33

 F

1.568

1.847

1.151

2.772

3.306

1.677

1.299

1.259

 p

0.079

0.028*

0.335

0.001*

0.000*

0.053

0.208

0.237

LP: PR

        

 Df

60,39

60, 39

60, 39

60, 39

60, 39

60, 39

60, 39

60, 39

 F

1.465

1.908

0.788

2.261

2.070

1.705

1.348

1.279

 p

0.103

0.017*

0.801

0.004*

0.009*

0.039*

0.161

0.208

LP: EST

        

 Df

69,30

69, 30

69, 30

69, 30

69, 30

69, 30

69, 30

69, 30

 F

1.238

2.222

1.367

2.211

5.082

1.059

1.912

1.176

 p

0.263

0.009*

0.173

0.009*

0.000*

0.443

0.026*

0.318

LP: PRL

        

 Df

55,43

55, 43

55, 43

55, 43

55, 43

55, 43

55, 43

55, 43

 F

2.718

2.332

2.177

2.664

6.420

1.823

1.748

2.180

 p

0.000*

0.002*

0.005*

0.001*

0.000*

0.001*

0.030*

0.005*

LP: LH:FSH

        

 Df

68,30

68, 30

68, 30

68, 30

68, 30

68, 30

68, 30

68, 30

 F

2.219

1.994

1.492

3.824

3.775

1.932

1.536

1.701

 p

0.009*

0.019*

0.114

0.000*

0.000*

0.024*

0.098

0.055

Testosterone

        

 Df

65,34

65, 34

65, 34

65, 34

65, 34

65, 34

65, 34

65, 34

 F

1.998

1.567

1.585

1.879

2.295

2.125

1.812

1.971

 p

0.015*

0.077

0.072

0.024*

0.005*

0.009*

0.030*

0.017*

  1. FP follicular phase, LP luteal phase, FSH follicle stimulating hormone, PR progesterone, EST estrogen, PRL prolactin, Df degree of freedom, F ANOVA value
  2. *Statistically significant
Back to article page